We are a UK biotech company that specialises in creating sheep monoclonal antibodies to power life-changing patient diagnostics.
We thrive on finding smarter answers to diagnose serious conditions. We have partnered with global in-vitro diagnostic companies for over 20 years, honing our skills in antibody technology to improve diagnostic testing. We also identify and initiate our own, in house opportunities to develop and create antibodies to improve the accessibility, accuracy and affordability of patient diagnosis.
Our high affinity sheep monoclonal antibodies (SMAs) have been used to optimise blood-testing diagnostics where conventional antibodies have failed, helping to diagnose and monitor heart disease, cancer, infertility and other serious conditions around the world.
Bioventix SMAs recognise difficult targets. We have created, developed and manufacture in excess of 20 SMAs which have become preferred reagents in IVD assays due to either increased affinity, greater specificity or improved affinity and specificity compared to other available antibodies, making them ideally suited for the development of biochemical tests that detect disease.
Our SMAs paired with our anti-complex sandwich partners offer exquisite recognition of small molecule targets, allowing for highly sensitive and specific ELISAs and lateral flow assays
We support healthcare organisations by creating new SMAs in around nine months, from the first step of immunisation through to production and finally the purified monoclonal antibodies for evaluation.
We offer a broad portfolio of SMAs for global clinical diagnostics and ELISA Kits to monitor exposure to industrial pollutants.
New Product
We now offer enzyme-linked immunosorbent assay (ELISA) kits for the detection of industrial pollutants in urine samples. This kit is the first of its kind to test for the biomarker HOP-G in just a few hours.
Our industrial biomonitoring platform aims to enhance employee care by reducing the time between sampling and actionable results from days or weeks to just hours, through point of exposure in-house lateral flow testing.
Peter Harrison
Chief Executive Officer
8 April 2024
Abstract Objectives To investigate whether circulating acute-phase brain-derived tau (BD-tau) is associated with functional outcome after ischemic stroke. Methods…
4 April 2024
Abstract Staging amyloid-beta (Aβ) pathophysiology according to the intensity of neurodegeneration could identify individuals at risk for cognitive decline…
The Bioventix team
In the year to 30 June 2023 our profits after tax increased by 9% to £8.4m
Demand for SMAs in the Chinese market continues to rise
Our new troponin assays are aiding the assessment of coronary issues
We continue working with one of the world’s leading labs on Alzheimer’s
Research and development is in our DNA, so we are always finding better ways to work, continually reducing our environmental impact and using our antibody technology to improve lives.
